| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Yehuda Shoenfeld | Q1515807 |
| Shaye Kivity | Q73295123 | ||
| Pnina Langevitz | Q73421809 | ||
| Ilan Ben-Zvi | Q37829259 | ||
| P2860 | cites work | Antimalarial Drug Toxicity | Q22061779 |
| Drugs for discoid lupus erythematosus | Q24240456 | ||
| Chloroquine is a potent inhibitor of SARS coronavirus infection and spread | Q24815979 | ||
| Cholesterol-lowering effect of hydroxychloroquine in patients with rheumatic disease: reversal of deleterious effects of steroids on lipids | Q41943371 | ||
| Hydroxychloroquine-induced toxic myopathy causing respiratory failure | Q41943600 | ||
| Hydroxychloroquine in decompensated, treatment-refractory noninsulin-dependent diabetes mellitus. A new job for an old drug? | Q41943988 | ||
| Mode of action of hydroxychloroquine in RA-evidence of an inhibitory effect on toll-like receptor signaling | Q41944676 | ||
| Granulomatous infiltration of the talus and abnormal vitamin D and calcium metabolism in a patient with sarcoidosis: successful treatment with hydroxychloroquine | Q41945060 | ||
| Effect of a malaria suppression program on the incidence of African Burkitt's lymphoma | Q41945980 | ||
| Hydroxychloroquine-induced cardiotoxicity in a 39-year-old woman with systemic lupus erythematosus and systolic dysfunction | Q41946807 | ||
| Sensory neuronopathy with Ro antibodies: response to combination immunosuppression | Q43136539 | ||
| Ocular toxicity and antenatal exposure to chloroquine or hydroxychloroquine for rheumatic diseases | Q43743058 | ||
| Treatment of generalized granuloma annulare with hydroxychloroquine | Q46641262 | ||
| Quinines--past and present | Q47842867 | ||
| Hydroxychloroquine reverses platelet activation induced by human IgG antiphospholipid antibodies. | Q50196335 | ||
| Oral mucosal hyperpigmentation secondary to antimalarial drug therapy. | Q50510120 | ||
| Respiratory function in systemic lupus erythematosus: relation with activity and severity. | Q51031044 | ||
| The history of antimalarials. | Q53622368 | ||
| Thrombosis and systemic lupus erythematosus: the Hopkins Lupus Cohort perspective | Q71500994 | ||
| Treatment of lupus erythematosus with mepacrine | Q75834093 | ||
| Ocular toxicity of hydroxychloroquine | Q81141186 | ||
| A cross-sectional study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome | Q28193536 | ||
| Eosinophilic fasciitis: clinical spectrum and therapeutic response in 52 cases | Q28293575 | ||
| Targeting lysosomal degradation induces p53-dependent cell death and prevents cancer in mouse models of lymphomagenesis | Q30480882 | ||
| The anti-HIV-1 activity of chloroquine | Q31884593 | ||
| Early induction of apoptosis in B-chronic lymphocytic leukaemia cells by hydroxychloroquine: activation of caspase-3 and no protection by survival factors | Q31893630 | ||
| Hydroxychloroquine in lupus pregnancy | Q33373145 | ||
| Effect of medication on microvascular vasodilatation in patients with systemic lupus erythematosus | Q33609077 | ||
| Chloroquine potentiates the anti-cancer effect of 5-fluorouracil on colon cancer cells | Q33632727 | ||
| Hydroxychloroquine protects the annexin A5 anticoagulant shield from disruption by antiphospholipid antibodies: evidence for a novel effect for an old antimalarial drug | Q33747286 | ||
| Effects of chloroquine on viral infections: an old drug against today's diseases? | Q33973620 | ||
| Adding chloroquine to conventional treatment for glioblastoma multiforme: a randomized, double-blind, placebo-controlled trial | Q33993957 | ||
| New concepts in antimalarial use and mode of action in dermatology | Q34007922 | ||
| Effect of chloroquine on insulin and glucose homoeostasis in normal subjects and patients with non-insulin-dependent diabetes mellitus | Q34068803 | ||
| Changes in glycosylated hemoglobin after initiation of hydroxychloroquine or methotrexate treatment in diabetes patients with rheumatic diseases | Q34354276 | ||
| Fluorescence probe measurement of the intralysosomal pH in living cells and the perturbation of pH by various agents | Q34556950 | ||
| Hydroxychloroquine and risk of diabetes in patients with rheumatoid arthritis | Q34648366 | ||
| The history of lupus erythematosus. From Hippocrates to Osler | Q34684696 | ||
| Effect of disease modifying agents on the lipid profiles of patients with rheumatoid arthritis | Q35547305 | ||
| Safety of hydroxychloroquine in pregnant patients with connective tissue diseases. Review of the literature | Q36049718 | ||
| Decrease in macrophage antigen catabolism caused by ammonia and chloroquine is associated with inhibition of antigen presentation to T cells | Q36275163 | ||
| Hydroxychloroquine and glycemia in women with rheumatoid arthritis and systemic lupus erythematosus | Q36277899 | ||
| Cardiomyopathy related to antimalarial therapy with illustrative case report | Q36521126 | ||
| Evaluation of the risk of anti-SSA/Ro-SSB/La antibody-associated cardiac manifestations of neonatal lupus in fetuses of mothers with systemic lupus erythematosus exposed to hydroxychloroquine | Q36672583 | ||
| Hydroxychloroquine directly reduces the binding of antiphospholipid antibody-beta2-glycoprotein I complexes to phospholipid bilayers | Q36843689 | ||
| Chloroquine ototoxicity | Q36861541 | ||
| Recycling of chloroquine and its hydroxyl analogue to face bacterial, fungal and viral infections in the 21st century | Q36880738 | ||
| Insights into atherosclerosis therapy in antiphospholipid syndrome | Q36984674 | ||
| Antiviral activity of chloroquine against human coronavirus OC43 infection in newborn mice | Q37274730 | ||
| Chloroquine and its analogs: a new promise of an old drug for effective and safe cancer therapies | Q37616407 | ||
| The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus | Q38446538 | ||
| Chloroquine, quinine, procaine, quinidine, tricyclic antidepressants, and methylxanthines as prostaglandin agonists and antagonists | Q39409324 | ||
| Hydroxychloroquine sulfate (Plaquenil) improves oral lichen planus: An open trial | Q39494741 | ||
| Hydroxychloroquine, chloroquine, and all-trans retinoic acid regulate growth, survival, and histone acetylation in breast cancer cells | Q39827707 | ||
| Chloroquine inhibits colon cancer cell growth in vitro and tumor growth in vivo via induction of apoptosis | Q39887289 | ||
| Cell growth inhibition, G2/M cell cycle arrest, and apoptosis induced by chloroquine in human breast cancer cell line Bcap-37. | Q39904465 | ||
| The efficacy and selectivity of tumor cell killing by Akt inhibitors are substantially increased by chloroquine | Q39952133 | ||
| Glucose-6-phosphate dehydrogenase deficiency: mechanisms of drug-induced hemolysis | Q40002985 | ||
| Chloroquine inhibits cell growth and induces cell death in A549 lung cancer cells | Q40329437 | ||
| Kikuchi-Fujimoto disease: an amazing response to hydroxychloroquine | Q40353377 | ||
| Anti-HIV effects of chloroquine: inhibition of viral particle glycosylation and synergism with protease inhibitors. | Q40568140 | ||
| Hydroxychloroquine inhibits calcium signals in T cells: a new mechanism to explain its immunomodulatory properties. | Q40877489 | ||
| The effects of chloroquine on serum 1,25-dihydroxyvitamin D and calcium metabolism in sarcoidosis | Q41473819 | ||
| The lysosomotropic amines, chloroquine and hydroxychloroquine: a potentially novel therapy for graft-versus-host disease | Q41475460 | ||
| Inhibition of human immunodeficiency virus type 1 replication by hydroxychloroquine in T cells and monocytes | Q41581307 | ||
| Palindromic rheumatism: a response to chloroquine | Q41887232 | ||
| Hydroxychloroquine, hydroxyurea and didanosine as initial therapy for HIV-infected patients with low viral load: safety, efficacy and resistance profile after 144 weeks | Q41912825 | ||
| Kikuchi-Fujimoto disease: hydroxychloroquine as a treatment | Q41913103 | ||
| Follow-up of infants exposed to hydroxychloroquine given to mothers during pregnancy and lactation | Q41913288 | ||
| In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine | Q41913526 | ||
| Chloroquine neuromyotoxicity. Clinical and pathologic perspective | Q41913997 | ||
| Hydroxychloroquine in polymorphic light eruption: a controlled trial with drug and visual sensitivity monitoring | Q41914026 | ||
| Hydroxychloroquine for the prevention of acute graft-versus-host disease after unrelated donor transplantation | Q41914903 | ||
| Effects of antimalarial drugs on phospholipase A and lysophospholipase activities in plasma membrane, mitochondrial, microsomal and cytosolic subcellular fractions of rat liver | Q41916861 | ||
| Control of mammary tumor cell growth in vitro by novel cell differentiation and apoptosis agents | Q41916902 | ||
| Hydroxychloroquine-induced apoptosis of chronic lymphocytic leukemia involves activation of caspase-3 and modulation of Bcl-2/bax/ratio | Q41917134 | ||
| Protective effect of hydroxychloroquine in systemic lupus erythematosus. Prospective long-term study of an Israeli cohort | Q41917167 | ||
| Evidence of transplacental passage of hydroxychloroquine in humans | Q41917690 | ||
| The effectiveness of hydroxychloroquine in patients with type 2 diabetes mellitus who are refractory to sulfonylureas--a randomized trial | Q41917902 | ||
| In Vivo Chloroquine-induced Inhibition of Insulin Degradation in a Diabetic Patient with Severe Insulin Resistance | Q41918190 | ||
| Low-dose oral chloroquine in the treatment of porphyria cutanea tarda | Q41918263 | ||
| Cutaneous lesions of dermatomyositis are improved by hydroxychloroquine | Q41919421 | ||
| Hydroxychloroquine has no significant effect on lipids and apolipoproteins in Chinese systemic lupus erythematosus patients with mild or inactive disease. | Q41921127 | ||
| Skeletal sarcoidosis: successful treatment with hydroxychloroquine. | Q41921137 | ||
| Inhibition of insulin metabolism by hydroxychloroquine and its enantiomers in cytosolic fraction of liver homogenates from healthy and diabetic rats | Q41924532 | ||
| The cholesterol lowering effect of antimalarial drugs is enhanced in patients with lupus taking corticosteroid drugs. | Q41924668 | ||
| Hypoglycemia induced by hydroxychloroquine in a type II diabetic treated for polyarthritis. | Q41924789 | ||
| A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group | Q41926859 | ||
| Hydroxychloroquine reverses thrombogenic properties of antiphospholipid antibodies in mice | Q41927420 | ||
| Lupus panniculitis treated by a combination therapy of hydroxychloroquine and quinacrine | Q41927634 | ||
| Hydroxychloroquine in prophylaxis of pulmonary embolism following hip arthroplasty | Q41927753 | ||
| Treatment of primary Sjögren's syndrome with hydroxychloroquine: a retrospective, open-label study. | Q41930645 | ||
| Chloroquine inhibits stimulated platelets at the arachidonic acid pathway | Q41933340 | ||
| Low-dose oral chloroquine in patients with porphyria cutanea tarda and low-moderate iron overload | Q41935315 | ||
| Rates and predictors of hydroxychloroquine retinal toxicity in patients with rheumatoid arthritis and systemic lupus erythematosus | Q41935707 | ||
| The lysosomotropic agent, hydroxychloroquine, delivered in a biodegradable nanoparticle system, overcomes drug resistance of B-chronic lymphocytic leukemia cells in vitro | Q41936477 | ||
| Hydroxychloroquine for subglottic stenosis: a novel therapy in the battle for air. | Q41936567 | ||
| Hydroxychloroquine compared with placebo in rheumatoid arthritis. A randomized controlled trial | Q41936586 | ||
| Effect of chloroquine phosphate treatment on serum MMP-9 and TIMP-1 levels in patients with systemic lupus erythematosus | Q41936831 | ||
| Hydroxychloroquine-induced myopathy | Q41936886 | ||
| Selective regulation of cytokine secretion by hydroxychloroquine: inhibition of interleukin 1 alpha (IL-1-alpha) and IL-6 in human monocytes and T cells. | Q41937744 | ||
| The lipid, lipoprotein, and apolipoprotein effects of hydroxychloroquine in patients with systemic lupus erythematosus. | Q41937905 | ||
| Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies. | Q41939439 | ||
| Growth inhibitory and differentiation effects of chloroquine and its analogue on human leukemic cells potentiate fetal hemoglobin production by targeting the polyamine pathway | Q41939577 | ||
| Immunologic concepts of light reactions in lupus erythematosus and polymorphous light eruptions. I. The mechanism of action of hydroxychloroquine | Q41941168 | ||
| Mode of action of chloroquine in patients with non-insulin-dependent diabetes mellitus | Q41941938 | ||
| Pregnancy outcome following first trimester exposure to chloroquine | Q41942091 | ||
| Vascular elasticity of systemic lupus erythematosus patients is associated with steroids and hydroxychloroquine treatment | Q41942164 | ||
| A randomized double-blind trial of hydroxychloroquine for the prevention of chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplantation. | Q41942186 | ||
| SPECTROPHOTOMETRIC STUDIES OF THE INTERACTION OF CHLOROQUINE WITH DEOXYRIBONUCLEIC ACID | Q41942706 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | malaria | Q12156 |
| hydroxychloroquine | Q421094 | ||
| antimalarial | Q521616 | ||
| anti-inflammatory agent | Q581996 | ||
| P304 | page(s) | 145-153 | |
| P577 | publication date | 2012-04-01 | |
| P1433 | published in | Clinical Reviews in Allergy & Immunology | Q1932354 |
| P1476 | title | Hydroxychloroquine: from malaria to autoimmunity | |
| P478 | volume | 42 |
| Q34389286 | A favorable effect of hydroxychloroquine on glucose and lipid metabolism beyond its anti-inflammatory role |
| Q41920381 | A new trick for an ancient drug: quinine dissociates antiphospholipid immune complexes |
| Q34103317 | Activation of the alternative NFκB pathway improves disease symptoms in a model of Sjogren's syndrome |
| Q28069143 | Anti-inflammatory and Immunomodulatory Effects of Antibiotics and Their Use in Dermatology |
| Q34184151 | Anti-malarials exert a protective effect while Mestizo patients are at increased risk of developing SLE renal disease: data from a Latin-American cohort |
| Q39420155 | Antimalarial drug chloroquine counteracts activation of indoleamine (2,3)-dioxygenase activity in human PBMC. |
| Q38242790 | Approaches for detecting lysosomal alkalinization and impaired degradation in fresh and cultured RPE cells: evidence for a role in retinal degenerations |
| Q41921823 | Associations of hydroxychloroquine use with lipid profiles in rheumatoid arthritis: pharmacologic implications |
| Q38131447 | Autoimmunity in 2012. |
| Q38976326 | Autophagic activity measured in whole rat hepatocytes as the accumulation of a novel BHMT fragment (p10), generated in amphisomes by the asparaginyl proteinase, legumain |
| Q58483027 | Autophagy Is a Tolerance-Avoidance Mechanism that Modulates TCR-Mediated Signaling and Cell Metabolism to Prevent Induction of T Cell Anergy |
| Q38034270 | Autophagy inhibition in cancer therapy: metabolic considerations for antitumor immunity |
| Q38666985 | Autophagy inhibitors |
| Q36193465 | Autophagy is associated with chemoresistance in neuroblastoma |
| Q38817806 | BMP type II receptor as a therapeutic target in pulmonary arterial hypertension. |
| Q99408059 | C-C chemokine receptor type 5 links COVID-19, rheumatoid arthritis, and Hydroxychloroquine: in silico analysis |
| Q37262533 | CONCURRENT WHOLE BRAIN RADIOTHERAPY AND SHORT-COURSE CHLOROQUINE IN PATIENTS WITH BRAIN METASTASES: A PILOT TRIAL |
| Q94469834 | COVID-19: Immunology and treatment options |
| Q94491475 | Candidate drugs against SARS-CoV-2 and COVID-19 |
| Q99610680 | Cardiovascular adverse events associated with hydroxychloroquine and chloroquine: A comprehensive pharmacovigilance analysis of pre-COVID-19 reports |
| Q37330468 | Cardiovascular disease in latin american patients with systemic lupus erythematosus: a cross-sectional study and a systematic review. |
| Q34081242 | Cardiovascular involvement in autoimmune diseases |
| Q59329150 | Chloroquine ameliorates carbon tetrachloride-induced acute liver injury in mice via the concomitant inhibition of inflammation and induction of apoptosis |
| Q97643153 | Chloroquine as a promising adjuvant therapy for type 1 Diabetes Mellitus |
| Q40354638 | Chloroquine attenuates TLR3/IFN-β signaling in cultured normal human mesangial cells: A possible protective effect against renal damage in lupus nephritis |
| Q34342236 | Chloroquine cardiomyopathy - a review of the literature |
| Q37410560 | Chloroquine reduces osteoclastogenesis in murine osteoporosis by preventing TRAF3 degradation |
| Q38855451 | Chloroquine rescues A549 cells from paraquat-induced death |
| Q91918269 | Clinical Trials during the SARS-CoV-2 Pandemic |
| Q93250708 | Covid-19 treatment update: follow the scientific evidence |
| Q54218397 | Current and Future Use of Chloroquine and Hydroxychloroquine in Infectious, Immune, Neoplastic, and Neurological Diseases: A Mini-Review. |
| Q92118099 | Dermatologists' Adherence to the Latest Recommendations for Screening of Hydroxychloroquine Retinopathy in Saudi Arabia: Cross-Sectional Study |
| Q36740874 | Design, synthesis and biological evaluation of novel antagonist compounds of Toll-like receptors 7, 8 and 9. |
| Q34353780 | Development of polyether urethane intravaginal rings for the sustained delivery of hydroxychloroquine |
| Q21092414 | Discovering thiamine transporters as targets of chloroquine using a novel functional genomics strategy |
| Q37145705 | Downregulation of Organic Anion Transporting Polypeptide (OATP) 1B1 Transport Function by Lysosomotropic Drug Chloroquine: Implication in OATP-Mediated Drug-Drug Interactions |
| Q26999453 | Drug repurposing and human parasitic protozoan diseases |
| Q36751710 | Effect of hydroxychloroquine and characterization of autophagy in a mouse model of endometriosis |
| Q39044818 | Effect of hydroxychloroquine on antiphospholipid antibody-induced changes in first trimester trophoblast function |
| Q94418532 | Effectiveness of Quinacrine (Mepacrine) in Photosensitive Autoimmune Diseases, Lupus Erythematosus, and Dermatomyositis: Report on 38 Cases and Literature Review |
| Q36355056 | Global survey of the immunomodulatory potential of common drugs. |
| Q95840390 | Host-microbiota interactions in immune-mediated diseases |
| Q35680679 | Hydroxychloroquine Destabilizes Phospho-S6 in Human Renal Carcinoma Cells |
| Q88376197 | Hydroxychloroquine Use and Risk of CKD in Patients with Rheumatoid Arthritis |
| Q97565704 | Hydroxychloroquine and the treatment of Sjogren syndrome, chronic ulcerative stomatitis, and oral lichen planus in the age of COVID-19 |
| Q52676433 | Hydroxychloroquine attenuates renal ischemia/reperfusion injury by inhibiting cathepsin mediated NLRP3 inflammasome activation. |
| Q36906782 | Hydroxychloroquine decreases Th17-related cytokines in systemic lupus erythematosus and rheumatoid arthritis patients |
| Q88674780 | Hydroxychloroquine fails to attenuate lesion development in a mouse model of neuromyelitis optica |
| Q38285841 | Hydroxychloroquine in children with interstitial (diffuse parenchymal) lung diseases |
| Q39031764 | Hydroxychloroquine in systemic lupus erythematosus (SLE). |
| Q36735689 | Hydroxychloroquine is ineffective in treatment of alopecia totalis and extensive alopecia areata: A case series of 8 patients |
| Q38282082 | Hydroxychloroquine preferentially induces apoptosis of CD45RO+ effector T cells by inhibiting autophagy: a possible mechanism for therapeutic modulation of T cells |
| Q36298100 | Hydroxychloroquine retinopathy: A review of imaging |
| Q35148912 | Hydroxychloroquine-inhibited dengue virus is associated with host defense machinery |
| Q91239723 | IITZ-01, a novel potent lysosomotropic autophagy inhibitor, has single-agent antitumor efficacy in triple-negative breast cancer in vitro and in vivo |
| Q28480517 | Identification of anti-malarial compounds as novel antagonists to chemokine receptor CXCR4 in pancreatic cancer cells |
| Q37522782 | Improving outcomes in patients with lupus and end-stage renal disease |
| Q39394982 | Increased autophagy in CD4+ T cells of rheumatoid arthritis patients results in T-cell hyperactivation and apoptosis resistance. |
| Q97594944 | Insights in chloroquine action: perspectives and implications in Malaria and COVID-19 |
| Q97533087 | Is hydroxychloroquine beneficial for COVID-19 patients? |
| Q36343593 | Low prevalence of Pneumocystis pneumonia in hospitalized patients with systemic lupus erythematosus: review of a clinical data warehouse |
| Q55332003 | Mast Cells Are Activated by Streptococcus pneumoniae In Vitro but Dispensable for the Host Defense Against Pneumococcal Central Nervous System Infection In Vivo. |
| Q27693200 | Modulation of neutrophil NETosis: interplay between infectious agents and underlying host physiology |
| Q35260971 | NF-κB-Mediated Regulation of Osteoclastogenesis |
| Q38697262 | Old and new therapeutics for Rheumatoid Arthritis: in vivo models and drug development |
| Q55222190 | Optical Coherence Tomography Minimum Intensity as an Objective Measure for the Detection of Hydroxychloroquine Toxicity. |
| Q97597053 | Pharmacokinetics and Pharmacological Properties of Chloroquine and Hydroxychloroquine in the Context of COVID-19 Infection |
| Q38630775 | Pharmacologic management of neuropsychiatric lupus |
| Q28119379 | Pharmacologic management of pain in patients with Chikungunya: a guideline |
| Q96686028 | Prevalence of hydroxychloroquine retinopathy using 2018 Royal College of Ophthalmologists diagnostic criteria |
| Q90302473 | Prevention of crystalline silica-induced inflammation by the anti-malarial hydroxychloroquine |
| Q95651180 | Prioritisation of Anti-SARS-Cov-2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human Pharmacokinetics |
| Q49269359 | Pro-apoptotic effect of doxycycline and hydroxychloroquine on B-cell lymphoma induced by C. burnetii |
| Q92129115 | Protective autophagy elicited by RAF→MEK→ERK inhibition suggests a treatment strategy for RAS-driven cancers |
| Q26744032 | Psoriasis, psoriatic arthritis, and rheumatoid arthritis: Is all inflammation the same? |
| Q35202866 | Quinidine, but not eicosanoid antagonists or dexamethasone, protect the gut from platelet activating factor-induced vasoconstriction, edema and paralysis |
| Q42150866 | Reciprocal effects of rab7 deletion in activated and neglected T cells |
| Q55046512 | Regulation of Organic Anion Transporting Polypeptides (OATP) 1B1- and OATP1B3-Mediated Transport: An Updated Review in the Context of OATP-Mediated Drug-Drug Interactions. |
| Q33612012 | Repositioning: the fast track to new anti-malarial medicines? |
| Q35877606 | Reproductive outcomes following hydroxychloroquine use for autoimmune diseases: a systematic review and meta-analysis |
| Q47162451 | Repurposing Drugs in Oncology (ReDO)-chloroquine and hydroxychloroquine as anti-cancer agents. |
| Q98386296 | Repurposing current therapeutic regimens against SARS-CoV-2 (Review) |
| Q94447174 | Respiratory conditions in coronavirus disease 2019 (COVID-19): Important considerations regarding novel treatment strategies to reduce mortality |
| Q99727438 | SARS-CoV-2 Infection and COVID-19 in 5 Patients in Ecuador After Prior Treatment with Hydroxychloroquine for Systemic Lupus Erythematosus |
| Q38411930 | Screening and vaccinations in patients requiring systemic immunosuppression: an update for dermatologists |
| Q38749963 | Serious Non-AIDS Events: Therapeutic Targets of Immune Activation and Chronic Inflammation in HIV Infection |
| Q37418140 | Serious Non-AIDS events: Immunopathogenesis and interventional strategies |
| Q38975509 | Signaling of chloroquine-induced stress in the yeast Saccharomyces cerevisiae requires the Hog1 and Slt2 mitogen-activated protein kinase pathways. |
| Q34574987 | Small molecule inhibitors of CXCR4. |
| Q38781354 | TLRs, future potential therapeutic targets for RA. |
| Q41703683 | Th-17 related regulatory network in the pathogenesis of Arab patients with systemic lupus erythematosus and lupus nephritis |
| Q26778494 | The Role of Autophagy in Lupus Nephritis |
| Q98627284 | The effect of 5-day course of hydroxychloroquine and azithromycin combination on QT interval in non-ICU COVID19(+) patients |
| Q110160267 | The evolution of knowledge on genes associated with human diseases |
| Q39152712 | The lysosomal inhibitor, chloroquine, increases cell surface BMPR-II levels and restores BMP9 signalling in endothelial cells harbouring BMPR-II mutations |
| Q37047827 | The origin and properties of extracellular DNA: from PAMP to DAMP. |
| Q94672281 | The possible mechanisms of action of 4-aminoquinolines (chloroquine/hydroxychloroquine) against Sars-Cov-2 infection (COVID-19): A role for iron homeostasis? |
| Q38561490 | Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases |
| Q38271125 | Treatment of severe lupus nephritis: the new horizon. |
| Q46207582 | Unconventional secretion of FABP4 by endosomes and secretory lysosomes. |
| Q38167718 | Unmet needs in respiratory diseases : "You can't know where you are going until you know where you have been"--Anonymous |
| Q38708002 | Upcoming Therapeutic Targets in Cutaneous Lupus Erythematous |
| Q51104578 | Use of Hydroxychloroquine Is Associated With Improved Lipid Profile in Rheumatoid Arthritis Patients. |
| Q36446926 | Use of disease-modifying antirheumatic drugs during pregnancy and risk of preeclampsia |
| Q92342635 | Wide field retinal imaging and the detection of drug associated retinal toxicity |
| Q52852647 | [Immunomodulatory therapy of autoimmune diseases : Quo vadis?]. |
Search more.